Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rapid identification of IDH1 and IDH2 mutations in acute myeloid leukaemia using high resolution melting curve analysis.
Noordermeer SM, Tönnissen E, Vissers I, van der Heijden A, van de Locht LT, Deutz-Terlouw PP, Marijt EW, Jansen JH, van der Reijden BA. Noordermeer SM, et al. Among authors: marijt ew. Br J Haematol. 2011 Feb;152(4):493-6. doi: 10.1111/j.1365-2141.2010.08423.x. Epub 2010 Oct 19. Br J Haematol. 2011. PMID: 20955413 Free article. No abstract available.
Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suciu S, Jansen JH. Aslanyan MG, et al. Among authors: marijt ew. Ann Hematol. 2014 Aug;93(8):1401-12. doi: 10.1007/s00277-014-2055-7. Epub 2014 Mar 29. Ann Hematol. 2014. PMID: 24994606
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R, Suciu S, Meloni G, Labar B, Marie JP, Halkes CJ, Muus P, Mistrik M, Amadori S, Specchia G, Fabbiano F, Nobile F, Sborgia M, Camera A, Selleslag DL, Lefrère F Sr, Magro D, Sica S, Cantore N, Beksac M, Berneman Z, Thomas X, Melillo L, Guimaraes JE, Leoni P, Luppi M, Mitra ME, Bron D, Fillet G, Marijt EW, Venditti A, Hagemeijer A, Mancini M, Jansen J, Cilloni D, Meert L, Fazi P, Vignetti M, Trisolini SM, Mandelli F, de Witte T. Willemze R, et al. Among authors: marijt ew. J Clin Oncol. 2014 Jan 20;32(3):219-28. doi: 10.1200/JCO.2013.51.8571. Epub 2013 Dec 2. J Clin Oncol. 2014. PMID: 24297940 Free article. Clinical Trial.
Phase I/II feasibility study evaluating the generation of leukemia-reactive cytotoxic T lymphocyte lines for treatment of patients with relapsed leukemia after allogeneic stem cell transplantation.
Marijt E, Wafelman A, van der Hoorn M, van Bergen C, Bongaerts R, van Luxemburg-Heijs S, van den Muijsenberg J, Wolbers JO, van der Werff N, Willemze R, Falkenburg F. Marijt E, et al. Haematologica. 2007 Jan;92(1):72-80. doi: 10.3324/haematol.10433. Haematologica. 2007. PMID: 17229638 Free article. Clinical Trial.
Multi-state analysis illustrates treatment success after stem cell transplantation for acute myeloid leukemia followed by donor lymphocyte infusion.
Eefting M, de Wreede LC, Halkes CJ, von dem Borne PA, Kersting S, Marijt EW, Veelken H, Putter H, Schetelig J, Falkenburg JH. Eefting M, et al. Among authors: marijt ew. Haematologica. 2016 Apr;101(4):506-14. doi: 10.3324/haematol.2015.136846. Epub 2016 Jan 22. Haematologica. 2016. PMID: 26802054 Free PMC article.
Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL.
Eefting M, Halkes CJ, de Wreede LC, van Pelt CM, Kersting S, Marijt EW, von dem Borne PA, Willemze R, Veelken H, Falkenburg JH. Eefting M, et al. Among authors: marijt ew. Bone Marrow Transplant. 2014 Feb;49(2):287-91. doi: 10.1038/bmt.2013.111. Epub 2013 Aug 12. Bone Marrow Transplant. 2014. PMID: 23933760
Patient HLA-DP-specific CD4+ T cells from HLA-DPB1-mismatched donor lymphocyte infusion can induce graft-versus-leukemia reactivity in the presence or absence of graft-versus-host disease.
Rutten CE, van Luxemburg-Heijs SA, Halkes CJ, van Bergen CA, Marijt EW, Oudshoorn M, Griffioen M, Falkenburg JH. Rutten CE, et al. Among authors: marijt ew. Biol Blood Marrow Transplant. 2013 Jan;19(1):40-8. doi: 10.1016/j.bbmt.2012.07.020. Epub 2012 Aug 4. Biol Blood Marrow Transplant. 2013. PMID: 22871556 Free article. Clinical Trial.
HLA class II upregulation during viral infection leads to HLA-DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion.
Stevanovic S, van Bergen CA, van Luxemburg-Heijs SA, van der Zouwen B, Jordanova ES, Kruisselbrink AB, van de Meent M, Harskamp JC, Claas FH, Marijt EW, Zwaginga JJ, Halkes CJ, Jedema I, Griffioen M, Falkenburg JH. Stevanovic S, et al. Among authors: marijt ew. Blood. 2013 Sep 12;122(11):1963-73. doi: 10.1182/blood-2012-12-470872. Epub 2013 Jun 18. Blood. 2013. PMID: 23777765 Free article. Clinical Trial.
48 results